EP Patent

EP1751136B1 — Nitrogenated heterocyclic derivatives as protein kinase modulators and use for the treatment of angiogenesis and cancer

Assigned to Amgen Inc · Expires 2014-07-02 · 12y expired

What this patent protects

Patent listed against lenvatinib-mesylate.

Drugs covered by this patent

lenvatinib-mesylate (LENVATINIB MESYLATE)

Patent Metadata

Patent number: EP1751136B1
Jurisdiction: EP
Classification: —
Expires: 2014-07-02
Drug substance claim: No
Drug product claim: No
Assignee: Amgen Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.